Cowen Downgrades Regulus Therapeutics (RGLS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- FedEx pilots ratify new collective bargaining agreement
- The real reason Meta shares are surging has nothing to do with its new AI model
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Regulus Reports Third Quarter 2016 Financial Results
November 1, 2016 4:10 PM EDTLA JOLLA, Calif., Nov. 1, 2016 /PRNewswire/ --Â Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the three and nine months ended September 30, 2016 and provided a summary of corporate highlights. Â
"Our focus in the third quarter included the advancement of the RG-012 development program and addressing the clinical... More
